458 Studies Now Enrolling
A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients with Advanced Prostate Cancer Refractory to Androgen Therapy
Study of HPN424 in Patients With Advanced Prostate Cancer
| Sponsor: | NA |
| Enrolling: | Male Patients Only |
| IRB Number: | AAAR8201 |
| U.S. Govt. ID: | NCT03577028 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to test the effectiveness and safety of an experimental drug known as HPN424 (also known as study drug) in patients with advanced prostate cancer. This drug has been tested in animals but not yet in people. This study tests different doses of HPN424. We want to find out how good the drug is at treating prostate cancer. We also want to find out what effects, good and/or bad, it has on patients and their cancer. HPN424 is an intravenous drug, meaning that it is administered through a needle placed in your vein. HPN424 is intended to stimulate patient's immune systems to attack the body's prostate cancer cells. It is an experimental drug, which means it is not approved by the U.S. Food and Drug Administration to treat cancer or any other disease.
This study is closed
Do You Qualify?
| Do you have a diagnosis of metastatic castrate-resistant prostate cancer (mCRPC)? | Yes | No |
| Have you received at least 2 prior systemic therapies approved for mCRPC? | Yes | No |
| Have you received ongoing androgen depletion therapy with a gonadotropin releasing hormone analog or inhibitor, or orchiectomy? | Yes | No |